Suchen
Korro Bio Inc
KRROZur Watchlist hinzufügen
12.050USD
-0.840-6.52%
Handelsschluss 05/08, 16:00（ET）Kurse um 15 Minuten verzögert
173.79MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Korro Bio Inc Unternehmen
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Korro Bio Inc Informationen
BörsenkürzelKRRO
Name des UnternehmensKorro Bio Inc
IPO-datumOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Anzahl der mitarbeiter104
WertpapierartOrdinary Share
GeschäftsjahresendeOct 03
AddresseOne Kendall Square. Building 600-700
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02139
Telefon16174681999
Websitehttps://www.korrobio.com/
BörsenkürzelKRRO
IPO-datumOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Führungskräfte von Korro Bio Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Pearson
Mr. Timothy R. Pearson
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
6.39M
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: 8 hours ago
Aktualisiert: 8 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Lynx1 Capital Advisors LLC
10.67%
New Enterprise Associates (NEA)
9.00%
Atlas Venture
7.88%
VR Adviser, LLC
7.00%
Point72 Asset Management, L.P.
5.66%
Andere
59.79%
Aktionäre
Aktionäre
Anteil
Lynx1 Capital Advisors LLC
10.67%
New Enterprise Associates (NEA)
9.00%
Atlas Venture
7.88%
VR Adviser, LLC
7.00%
Point72 Asset Management, L.P.
5.66%
Andere
59.79%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
36.98%
Venture Capital
24.28%
Hedge Fund
13.54%
Investment Advisor/Hedge Fund
4.01%
Research Firm
3.19%
Individual Investor
0.56%
Bank and Trust
0.07%
Pension Fund
0.05%
Andere
17.33%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
215
11.84M
86.30%
+782.64K
2025Q4
193
11.05M
117.36%
+1.14M
2025Q3
186
9.33M
99.33%
-1.07M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Lynx1 Capital Advisors LLC
677.91K
4.7%
+677.91K
--
Dec 31, 2025
New Enterprise Associates (NEA)
1.30M
9%
+207.10K
+18.99%
Mar 10, 2026
Atlas Venture
1.14M
7.88%
--
--
Dec 31, 2025
VR Adviser, LLC
1.01M
7%
+1.01M
--
Mar 10, 2026
Point72 Asset Management, L.P.
816.88K
5.66%
+816.88K
--
Mar 10, 2026
Nantahala Capital Management, LLC
600.00K
4.16%
+600.00K
--
Dec 31, 2025
Vanguard Investments Australia Ltd.
489.64K
3.39%
+489.64K
--
Dec 31, 2025
The Vanguard Group, Inc.
489.64K
3.39%
+93.98K
+23.75%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
419.30K
2.91%
+10.58K
+2.59%
Dec 31, 2025
TCG Crossover Management, LLC
416.30K
2.89%
--
--
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.05%
Avantis US Small Cap Equity ETF
Anteil0.02%
Global X Russell 2000 ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0%
SPDR Portfolio MSCI Global Stock Market ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
iShares Russell 3000 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Datum
Ex-Dividendentag
Art
Verhältnis
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
